单药泰索帝治疗PS≥2晚期乳腺癌患者的疗效和安全性  

Efficacy and safety in advanced breast cancer patients with PS≥2 treated with taxotere as a single agent

作　　者：刘芳[1] 冯胜强[2] 徐一石[3] 杨清明[1] 彭朝津[1] 

机构地区：[1]解放军总医院第一附属医院临床部干部病房,北京100037 [2]总参谋部警卫局保健处,北京100017 [3]北京军区总医院普外科,北京100040

出　　处：《第四军医大学学报》2008年第2期175-177,共3页Journal of the Fourth Military Medical University

摘　　要：目的:分析PS≥2晚期乳腺癌患者单药泰索帝治疗的疗效与安全性.方法:33例PS≥2晚期乳腺癌患者,均可评价疗效.11例患者接受每3周方案,中位剂量为75(70.7～86.1)mg/m2;22例患者接受每周方案,中位剂量为25(20.4～28.7)mg/m2.结果:①总有效率为27.3%,CR0例,PR9例,SD18例,PD6例,SD达6mo2例(均为每周方案患者),临床获益率33.3%.每周方案及每三周方案有效率分别为22.7%和36.4%,3例患者死亡.中位TTP时间为3.5(1～7)mo.②KPS基线时均值62.1±10.8,化疗后均值为69.4±13.9,两组比较有统计学差异(P=0.002),其中51.5%(17/33)的患者KPS评分增加,39.4%的患者体质量增加.③53.7%的化疗周期出现Ⅲ-Ⅳ度粒细胞减低.其中每3周方案中87.5%的周期出现Ⅲ-Ⅳ度粒细胞减低,毒性大;而每周方案仅39.5%周期Ⅲ-Ⅳ度粒细胞毒性,耐受性较好,两组比较有统计学差异(P=0.002).结论:单药泰索帝治疗PS≥2晚期乳腺癌有一定疗效,每周方案更易耐受.AIM： To evaluate the efficacy and toxicity in advanced breast cancer patients with PS ≥2 treated with taxotere as a single agent. METHODS： Thirty-three advanced breast cancer patients with PS ≥2 received taxotere as a single agent. Eleven patients were given at a dose of 70.7-86. 1 mg/m^2 every three weeks, median delivered dose was 75 mg/m^2, and the other 22 patients were given at a dose of 20.4-28.7 mg/m^2 weekly, median delivered dose was 25 mg/m^2. All patients were evaluated for toxicity and response. RESULTS： （1） The overall response rate in this group of advanced breast cancer was 27.3%. Nine patients achieved partial response, 18 patients had stable disease （2 patients had stable disease for over 6 months ） , 6 patients had progressed,and 3 patients were dead. The rate of clinical benefit was 33.3%. The response rates in patients treated weekly or every 3 weeks were 22.7% and 36.4% , respectively . Median time to progression （ TTP ） was 3.5 （1-7） months. （2） Mean KPS increased from （62.1±10.8） at baseline to （69.4±13.9） after chemotherapy （ P = 0. 002）. KPS of 51.5% patients and weight of 39.4% patients were increased. （3） GradeⅢ-Ⅳ neutropenia was found in 53.7% cycles. It was found in 87.5% cycles when taxotere was given every 3 weeks and in 39.5% cycles when given weekly. Weekly given taxotere was generally well tolerated, and the difference was significant between the 2 groups （P = 0. 002）. CONCLUSION： Taxotere as a single agent therapy is effective, and weeklv taxotere therapy is well tolerated in advanced breast cancer patients with PS≥2.

关 键 词：乳腺肿瘤 PS≥2 泰索帝 治疗结果 药物安全性 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]